Meseret Jeldu, Abraham Fessehaye Sium, Bethel Dereje
{"title":"Clinical characteristics and treatment outcomes of Vulvar cancer patients at a tertiary setting in Ethiopia: A 6-year review","authors":"Meseret Jeldu, Abraham Fessehaye Sium, Bethel Dereje","doi":"10.1016/j.cson.2024.100068","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To describe clinical characteristics and treatment outcomes of vulvar cancer patients managed at a gynecologic oncology treatment center in Ethiopia.</div></div><div><h3>Methods and materials</h3><div>This was a 6-year review of vulvar cancers patients (with and without HIV co-infection) that were managed at St. Paul’s Hospital Millennium Medical College (Ethiopia) between 2017 and 2022. Data were extracted from patient’s medical records using a data extraction tool. Data were analyzed using SPSS version 26. Simple descriptive statistics and Chi-squared test were carried out as appropriate.</div></div><div><h3>Results</h3><div>After excluding 10 patients for incomplete data, a total of 96 patients were included in the final analysis, out of which 65(67.7%) patients had HIV co-infection. Surgery with or without chemotherapy was the most common (62/96, 64.8%) treatment modality provided for the patients while the remaining 34 patients were treated with primary chemoradiation. Among those who had surgery, the majority of them (43/62, 69.4%) were managed with surgery alone, followed by another 16(25.8%) patients who were treated with neoadjuvant chemotherapy followed by surgery.</div></div><div><h3>Conclusion</h3><div>In this study, most vulvar cancer patients (more than three-quarters) had favorable survival outcomes at a median follow-up of 3 years post-standard treatment for vulvar cancer.</div></div>","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"3 4","pages":"Article 100068"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Surgical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2773160X24000369","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
To describe clinical characteristics and treatment outcomes of vulvar cancer patients managed at a gynecologic oncology treatment center in Ethiopia.
Methods and materials
This was a 6-year review of vulvar cancers patients (with and without HIV co-infection) that were managed at St. Paul’s Hospital Millennium Medical College (Ethiopia) between 2017 and 2022. Data were extracted from patient’s medical records using a data extraction tool. Data were analyzed using SPSS version 26. Simple descriptive statistics and Chi-squared test were carried out as appropriate.
Results
After excluding 10 patients for incomplete data, a total of 96 patients were included in the final analysis, out of which 65(67.7%) patients had HIV co-infection. Surgery with or without chemotherapy was the most common (62/96, 64.8%) treatment modality provided for the patients while the remaining 34 patients were treated with primary chemoradiation. Among those who had surgery, the majority of them (43/62, 69.4%) were managed with surgery alone, followed by another 16(25.8%) patients who were treated with neoadjuvant chemotherapy followed by surgery.
Conclusion
In this study, most vulvar cancer patients (more than three-quarters) had favorable survival outcomes at a median follow-up of 3 years post-standard treatment for vulvar cancer.
目的分析埃塞俄比亚某妇科肿瘤治疗中心外阴癌患者的临床特点及治疗效果。方法和材料这是一项对2017年至2022年期间在圣保罗医院千年医学院(埃塞俄比亚)管理的外阴癌患者(伴有和不伴有HIV合并感染)的6年综述。使用数据提取工具从患者的医疗记录中提取数据。数据分析采用SPSS version 26。适当时进行简单描述性统计和卡方检验。结果在排除10例资料不全患者后,最终纳入96例患者,其中65例(67.7%)合并HIV感染。手术加或不加化疗是患者最常见的治疗方式(62/96,64.8%),其余34例患者接受原发性放化疗。手术患者中以单纯手术为主(43/62,69.4%),手术后新辅助化疗为主(16例,25.8%)。在这项研究中,大多数外阴癌患者(超过四分之三)在外阴癌标准治疗后的中位随访3年有良好的生存结果。